IL133008A0 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases - Google Patents

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Info

Publication number: IL133008A0
Authority: IL; Israel
Prior art keywords: quinoline; growth factor; derived growth; tyrosine kinases; inhibit platelet
Prior art date: 1997-05-28

Application number

IL13300898A

Other languages

English (en)

Original Assignee

Aventis Pharm Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-28

Filing date

1998-05-28

Publication date

2001-03-19

1998-05-28 Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc

2001-03-19 Publication of IL133008A0 publication Critical patent/IL133008A0/xx

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 title 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 title 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

IL13300898A 1997-05-28 1998-05-28 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases IL133008A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86445597A	1997-05-28	1997-05-28
US97261497A	1997-11-18	1997-11-18
PCT/US1998/011000 WO1998054157A1 (fr)	1997-05-28	1998-05-28	COMPOSES DE QUINOLINE ET DE QUINOXALINE INHIBANT LE FACTEUR DE CROISSANCE DERIVE DES PLAQUETTES ET/OU LES TYROSINE-KINASES p56?lck¿

Publications (1)

Publication Number	Publication Date
IL133008A0 true IL133008A0 (en)	2001-03-19

Family

ID=27127839

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL13300898A IL133008A0 (en)	1997-05-28	1998-05-28	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
IL13300798A IL133007A (en)	1997-05-28	1998-05-28	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
IL13300998A IL133009A0 (en)	1997-05-28	1998-05-28	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL13300798A IL133007A (en)	1997-05-28	1998-05-28	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
IL13300998A IL133009A0 (en)	1997-05-28	1998-05-28	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Country Status (25)

Country	Link
EP (3)	EP1001945B1 (fr)
JP (3)	JP2002500676A (fr)
KR (2)	KR100440756B1 (fr)
CN (3)	CN1261353A (fr)
AP (3)	AP1362A (fr)
AT (3)	ATE493389T1 (fr)
AU (3)	AU742739B2 (fr)
BG (3)	BG64419B1 (fr)
BR (3)	BR9809172A (fr)
CA (3)	CA2291774A1 (fr)
CZ (3)	CZ298521B6 (fr)
DE (3)	DE69828607T2 (fr)
DK (1)	DK0991628T3 (fr)
EA (4)	EA008136B1 (fr)
ES (1)	ES2235331T3 (fr)
HU (2)	HUP0002084A3 (fr)
IL (3)	IL133008A0 (fr)
NO (3)	NO323720B1 (fr)
OA (3)	OA11222A (fr)
PL (3)	PL195552B1 (fr)
PT (1)	PT991628E (fr)
SI (1)	SI0991628T1 (fr)
SK (4)	SK158199A3 (fr)
UA (1)	UA57790C2 (fr)
WO (3)	WO1998054157A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180632B1 (en)	1997-05-28	2001-01-30	Aventis Pharmaceuticals Products Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
SI0991628T1 (en) *	1997-05-28	2005-06-30	Aventis Pharmaceuticals Inc	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6159978A (en) *	1997-05-28	2000-12-12	Aventis Pharmaceuticals Product, Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) *	1997-05-28	2001-06-12	Aventis Pharmaceuticals Products, Inc	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en)	1999-02-24	1999-04-14	Zeneca Ltd	Quinoline derivatives
US6506769B2 (en)	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en)	1999-11-30	2006-09-05	Pfizer Inc.	2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2002014319A2 (fr)	2000-08-11	2002-02-21	Boehringer Ingelheim Pharmaceuticals, Inc.	Composes heterocycliques utiles en tant qu'inhibiteurs de tyrosine kinases
RU2309154C9 (ru)	2002-03-27	2016-09-27	Глэксо Груп Лимитед	3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
DE10237423A1 (de) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE602004000260T2 (de)	2003-07-22	2006-08-24	Arena Pharmaceuticals, Inc., San Diego	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GT200500008A (es)	2004-01-16	2005-08-16		Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
PE20090288A1 (es)	2007-05-10	2009-04-03	Smithkline Beecham Corp	Derivados de quinoxalina como inhibidores de la pi3 quinasa
EP2508177A1 (fr)	2007-12-12	2012-10-10	Glaxo Group Limited	Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2241557A1 (fr)	2009-04-02	2010-10-20	Æterna Zentaris GmbH	Dérivés de chinoxaline et leur utilisation pour le traitement de tumeurs bénignes et malignes
JP5728683B2 (ja)	2009-09-04	2015-06-03	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
CN101823998B (zh) *	2010-05-05	2015-03-25	江苏利田科技股份有限公司	一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
DK2624695T3 (en)	2010-10-08	2016-01-04	Nivalis Therapeutics Inc	NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
AU2011343518B2 (en)	2010-12-16	2016-11-10	Nivalis Therapeutics, Inc.	Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
WO2013135612A1 (fr)	2012-03-14	2013-09-19	Bayer Intellectual Property Gmbh	Imidazopyridazines substituées
MX371331B (es)	2012-04-24	2020-01-27	Vertex Pharma	Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
RS58514B1 (sr)	2012-06-13	2019-04-30	Incyte Holdings Corp	Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
ME03336B (fr)	2013-03-12	2019-10-20	Vertex Pharma	Inhibiteurs d'adn-pk
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
AP2015008898A0 (en)	2013-06-11	2015-12-31	Bayer Pharma AG	Prodrug derivatives of substituted triazolopyridines
JP6408569B2 (ja)	2013-10-17	2018-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HRP20210319T1 (hr)	2014-03-26	2021-04-30	Astex Therapeutics Ltd.	Kombinacije inhibitora fgfr i inhibitora igf1r
RU2715236C2 (ru)	2014-03-26	2020-02-26	Астекс Терапьютикс Лтд	Комбинации
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI719960B (zh)	2015-02-10	2021-03-01	英商阿斯迪克治療公司	新穎組成物
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
US10022355B2 (en)	2015-06-12	2018-07-17	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt)	2015-07-15	2018-09-04	Axovant Sciences Gmbh	resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
WO2017044766A1 (fr)	2015-09-10	2017-03-16	Nivalis Therapeutics, Inc.	Formes solides d'un inhibiteur de s-nitrosoglutathione réductase
EP3353164B1 (fr)	2015-09-23	2021-11-03	Janssen Pharmaceutica, N.V.	1,4-benzodiazepines bi-heteroaryl substituees et leurs utilisations pour le traitement du cancer
US11155555B2 (en)	2015-09-23	2021-10-26	Janssen Pharmaceutica Nv	Compounds
EP3518931A4 (fr)	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	Méthode de traitement du cancer utilisant une combinaison d'agents endommageant l'adn et d'inhibiteurs de la dna-pk
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20241288T1 (hr)	2018-05-04	2024-12-06	Incyte Corporation	Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CA3157361A1 (fr)	2019-10-14	2021-04-22	Incyte Corporation	Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP7832891B2 (ja)	2019-12-04	2026-03-18	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の誘導体
CA3163875A1 (fr)	2019-12-04	2021-06-10	Incyte Corporation	Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (fr)	2021-04-12	2022-10-20	Incyte Corporation	Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
CA3220155A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3483704D1 (de) *	1983-07-22	1991-01-17	Du Pont	Phenylchinolinsaeure und derivate als antitumormittel.
US4888427A (en) *	1987-04-07	1989-12-19	University Of Florida	Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) *	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
SG64322A1 (en) *	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NO940245D0 (no) *	1993-01-28	1994-01-24	Takeda Chemical Industries Ltd	Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
DE4426373A1 (de) *	1994-07-26	1996-02-01	Bayer Ag	3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
US6211215B1 (en) *	1996-07-19	2001-04-03	Takeda Chemical Industries, Ltd.	Heterocyclic compounds, their production and use
WO1998031228A1 (fr) *	1997-01-21	1998-07-23	Nissan Chemical Industries, Ltd.	Agents antimicrobiens/imputrescibilisants industriels, agents algicides et antiparasites contenant des n-quinoxalylanilines
SI0991628T1 (en) *	1997-05-28	2005-06-30	Aventis Pharmaceuticals Inc	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES

1998
- 1998-05-28 SI SI9830741T patent/SI0991628T1/ unknown
- 1998-05-28 ES ES98925022T patent/ES2235331T3/es not_active Expired - Lifetime
- 1998-05-28 CN CN98806430A patent/CN1261353A/zh active Pending
- 1998-05-28 EP EP98925041A patent/EP1001945B1/fr not_active Expired - Lifetime
- 1998-05-28 DE DE69828607T patent/DE69828607T2/de not_active Expired - Lifetime
- 1998-05-28 SK SK1581-99A patent/SK158199A3/sk unknown
- 1998-05-28 IL IL13300898A patent/IL133008A0/xx not_active IP Right Cessation
- 1998-05-28 KR KR10-1999-7011036A patent/KR100440756B1/ko not_active Expired - Fee Related
- 1998-05-28 CZ CZ0415899A patent/CZ298521B6/cs not_active IP Right Cessation
- 1998-05-28 DE DE69842077T patent/DE69842077D1/de not_active Expired - Lifetime
- 1998-05-28 HU HU0002084A patent/HUP0002084A3/hu unknown
- 1998-05-28 CZ CZ0417999A patent/CZ298490B6/cs not_active IP Right Cessation
- 1998-05-28 AU AU78037/98A patent/AU742739B2/en not_active Ceased
- 1998-05-28 AT AT98926129T patent/ATE493389T1/de not_active IP Right Cessation
- 1998-05-28 CZ CZ0418099A patent/CZ296845B6/cs not_active IP Right Cessation
- 1998-05-28 EA EA199901092A patent/EA008136B1/ru not_active IP Right Cessation
- 1998-05-28 AT AT98925022T patent/ATE286886T1/de not_active IP Right Cessation
- 1998-05-28 EA EA199901090A patent/EA004103B1/ru not_active IP Right Cessation
- 1998-05-28 WO PCT/US1998/011000 patent/WO1998054157A1/fr not_active Ceased
- 1998-05-28 BR BR9809172-7A patent/BR9809172A/pt not_active Application Discontinuation
- 1998-05-28 PT PT98925022T patent/PT991628E/pt unknown
- 1998-05-28 CA CA002291774A patent/CA2291774A1/fr not_active Abandoned
- 1998-05-28 AP APAP/P/1999/001711A patent/AP1362A/en active
- 1998-05-28 WO PCT/US1998/011036 patent/WO1998054158A1/fr not_active Ceased
- 1998-05-28 PL PL98337087A patent/PL195552B1/pl not_active IP Right Cessation
- 1998-05-28 KR KR10-1999-7010972A patent/KR100425638B1/ko not_active Expired - Fee Related
- 1998-05-28 DK DK98925022T patent/DK0991628T3/da active
- 1998-05-28 WO PCT/US1998/010999 patent/WO1998054156A1/fr not_active Ceased
- 1998-05-28 PL PL98337084A patent/PL194670B1/pl not_active IP Right Cessation
- 1998-05-28 AU AU77079/98A patent/AU751188C/en not_active Ceased
- 1998-05-28 DE DE69842151T patent/DE69842151D1/de not_active Expired - Lifetime
- 1998-05-28 EA EA199901086A patent/EA002600B1/ru not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001709A patent/AP1444A/en active
- 1998-05-28 HU HU0004807A patent/HUP0004807A3/hu unknown
- 1998-05-28 CN CN98806454A patent/CN1280572A/zh active Pending
- 1998-05-28 AT AT98925041T patent/ATE500233T1/de not_active IP Right Cessation
- 1998-05-28 CA CA002291728A patent/CA2291728A1/fr not_active Abandoned
- 1998-05-28 IL IL13300798A patent/IL133007A/xx not_active IP Right Cessation
- 1998-05-28 CA CA002291750A patent/CA2291750A1/fr not_active Abandoned
- 1998-05-28 PL PL337086A patent/PL194980B1/pl unknown
- 1998-05-28 SK SK114-2005A patent/SK286084B6/sk not_active IP Right Cessation
- 1998-05-28 BR BR9809501-3A patent/BR9809501A/pt not_active Application Discontinuation
- 1998-05-28 SK SK1579-99A patent/SK157999A3/sk unknown
- 1998-05-28 JP JP50098799A patent/JP2002500676A/ja not_active Ceased
- 1998-05-28 EP EP98926129A patent/EP1001946B1/fr not_active Expired - Lifetime
- 1998-05-28 UA UA99127137A patent/UA57790C2/uk unknown
- 1998-05-28 JP JP50096599A patent/JP2002500675A/ja not_active Ceased
- 1998-05-28 SK SK1580-99A patent/SK158099A3/sk unknown
- 1998-05-28 AU AU77062/98A patent/AU747026B2/en not_active Ceased
- 1998-05-28 EP EP98925022A patent/EP0991628B1/fr not_active Expired - Lifetime
- 1998-05-28 IL IL13300998A patent/IL133009A0/xx not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001710A patent/AP1554A/en active
- 1998-05-28 JP JP50096499A patent/JP2002513417A/ja not_active Ceased
- 1998-05-28 BR BR9809515-3A patent/BR9809515A/pt not_active Application Discontinuation
- 1998-05-28 CN CNB98806538XA patent/CN1140516C/zh not_active Expired - Fee Related
1999
- 1999-11-23 EA EA200100575A patent/EA007807B1/ru not_active IP Right Cessation
- 1999-11-26 NO NO19995818A patent/NO323720B1/no unknown
- 1999-11-26 NO NO19995817A patent/NO316377B1/no unknown
- 1999-11-26 NO NO19995819A patent/NO323721B1/no unknown
- 1999-11-29 OA OA9900262A patent/OA11222A/en unknown
- 1999-11-29 OA OA9900261A patent/OA11221A/en unknown
- 1999-11-29 OA OA9900260A patent/OA11264A/en unknown
- 1999-12-08 BG BG103965A patent/BG64419B1/bg unknown
- 1999-12-08 BG BG103963A patent/BG64444B1/bg unknown
- 1999-12-14 BG BG104006A patent/BG64445B1/bg unknown

Also Published As

Publication number	Publication date
CN1280572A (zh)	2001-01-17
DE69842077D1 (de)	2011-02-10
BG64419B1 (bg)	2005-01-31
AP1362A (en)	2005-01-19
NO995819D0 (no)	1999-11-26
NO323720B1 (no)	2007-06-25
IL133009A0 (en)	2001-03-19
DK0991628T3 (da)	2005-05-17
DE69842151D1 (de)	2011-04-14
EA200100575A1 (ru)	2002-02-28
OA11264A (en)	2002-11-19
CZ417999A3 (cs)	2000-05-17
PL195552B1 (pl)	2007-10-31
IL133007A0 (en)	2001-03-19
SI0991628T1 (en)	2005-06-30
CN1261354A (zh)	2000-07-26
SK158199A3 (en)	2000-06-12
EP1001945A1 (fr)	2000-05-24
CZ418099A3 (cs)	2000-05-17
ATE500233T1 (de)	2011-03-15
KR20010039512A (ko)	2001-05-15
BR9809515A (pt)	2000-06-20
KR100425638B1 (ko)	2004-04-03
CZ298490B6 (cs)	2007-10-17
AU747026B2 (en)	2002-05-09
BR9809172A (pt)	2000-08-01
WO1998054156A1 (fr)	1998-12-03
AU7803798A (en)	1998-12-30
WO1998054157A1 (fr)	1998-12-03
NO995817D0 (no)	1999-11-26
BG103963A (en)	2000-07-31
AP9901709A0 (en)	1999-12-31
AU751188C (en)	2005-06-30
HUP0004807A2 (hu)	2001-11-28
NO995817L (no)	1999-11-26
BR9809501A (pt)	2000-06-20
EP0991628B1 (fr)	2005-01-12
PL337084A1 (en)	2000-07-31
EA008136B1 (ru)	2007-04-27
CA2291774A1 (fr)	1998-12-03
IL133007A (en)	2005-06-19
KR20010013057A (ko)	2001-02-26
CZ296845B6 (cs)	2006-07-12
NO995818D0 (no)	1999-11-26
AP9901711A0 (en)	1999-12-31
ATE493389T1 (de)	2011-01-15
AP9901710A0 (en)	1999-12-31
EA199901086A1 (ru)	2000-06-26
BG104006A (en)	2000-07-31
AU742739B2 (en)	2002-01-10
PL337086A1 (en)	2000-07-31
CA2291750A1 (fr)	1998-12-03
ATE286886T1 (de)	2005-01-15
BG64445B1 (en)	2005-02-28
WO1998054158A1 (fr)	1998-12-03
OA11221A (en)	2003-07-16
UA57790C2 (uk)	2003-07-15
NO316377B1 (no)	2004-01-19
PL194980B1 (pl)	2007-07-31
EP1001945B1 (fr)	2011-03-02
AU7707998A (en)	1998-12-30
CZ415899A3 (cs)	2000-05-17
DE69828607T2 (de)	2006-01-05
BG64444B1 (en)	2005-02-28
EP1001946A1 (fr)	2000-05-24
HUP0002084A3 (en)	2000-12-28
JP2002500676A (ja)	2002-01-08
KR100440756B1 (ko)	2004-07-21
CA2291728A1 (fr)	1998-12-03
NO995818L (no)	1999-11-26
PT991628E (pt)	2005-05-31
HUP0002084A2 (hu)	2000-10-28
BG103965A (en)	2000-07-31
NO995819L (no)	1999-11-26
EA199901090A1 (ru)	2000-08-28
NO323721B1 (no)	2007-06-25
JP2002513417A (ja)	2002-05-08
EP0991628A4 (fr)	2000-07-26
SK286084B6 (sk)	2008-03-05
SK158099A3 (en)	2000-06-12
PL194670B1 (pl)	2007-06-29
EA199901092A1 (ru)	2000-06-26
AP1444A (en)	2005-07-18
EA002600B1 (ru)	2002-06-27
CN1261353A (zh)	2000-07-26
SK157999A3 (en)	2000-06-12
AP1554A (en)	2006-01-18
EP0991628A1 (fr)	2000-04-12
AU7706298A (en)	1998-12-30
EP1001945A4 (fr)	2000-07-26
DE69828607D1 (de)	2005-02-17
ES2235331T3 (es)	2005-07-01
PL337087A1 (en)	2000-07-31
EP1001946A4 (fr)	2000-07-26
JP2002500675A (ja)	2002-01-08
EA007807B1 (ru)	2007-02-27
AU751188B2 (en)	2002-08-08
EA004103B1 (ru)	2003-12-25
CZ298521B6 (cs)	2007-10-24
EP1001946B1 (fr)	2010-12-29
HUP0004807A3 (en)	2001-12-28
HK1028042A1 (en)	2001-02-02
CN1140516C (zh)	2004-03-03
OA11222A (en)	2003-07-16

Legal Events

Date	Code	Title
2005-07-25	FF	Patent granted
2005-09-25	KB	Patent renewed
2008-08-10	KB	Patent renewed
2013-02-03	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL133007A0 (en)	2001-03-19	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
PL348605A1 (en)	2002-06-03	Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
PL348979A1 (en)	2002-06-17	Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
IL143405A0 (en)	2002-04-21	Quinoline and quinoxaline compounds
IL134013A0 (en)	2001-04-30	Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUS1700048I1 (hu)	2017-12-28	Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
PL346934A1 (en)	2002-03-11	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
IL137041A0 (en)	2001-06-14	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PL331154A1 (en)	1999-06-21	Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
ZA200108015B (en)	2003-03-26	Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases.
AU3885900A (en)	2000-10-09	Inhibitors of the egf-receptor tyrosine kinase and their use
ZA984573B (en)	1999-01-21	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
HUP0002219A3 (en)	2001-01-29	Quinoline and quinoxaline derivatives which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases and pharmaceutical compositions containing them
HK1038554A (en)	2002-03-22	Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
HK1038229A (en)	2002-03-08	Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
ZA9710727B (en)	1998-06-12	Substituted pyrimidine compounds and methods of use.
HK1038555A (en)	2002-03-22	Quinoline and quinoxaline compounds
GB9600997D0 (en)	1996-03-20	N-indolinyl-pyridopyrimidines as tyrosine kinase inhibitors